Skip to main content
. 2017 Feb 23;61(3):e02252-16. doi: 10.1128/AAC.02252-16

TABLE 2.

Antimicrobial activity of ceftazidime-avibactam tested against P. aeruginosa from U.S. medical centers (2012 to 2015)

Resistance groupb No. (cumulative %) of isolates at MIC (mg/liter):
MIC50 (mg/liter) MIC90 (mg/liter)
≤0.25 0.5 1 2 4 8 16 32 >32
All isolates (n = 7,452) 128 (1.7) 390 (7.0) 2,843 (45.1) 2,409 (77.4) 1,043 (91.4) 415 (97.0)a 133 (98.8) 44 (99.4) 47 (100.0) 2 4
CAZ-NS (≥16 mg/liter; n = 1,168) 2 (0.2) 8 (0.9) 88 (8.4) 282 (32.5) 320 (59.9) 246 (81.0)a 131 (92.2) 44 (96.0) 47 (100.0) 4 16
MEM-NS (≥4 mg/liter; n = 1,341) 2 (0.1) 10 (0.9) 127 (10.4) 323 (34.5) 416 (65.5) 278 (86.2)a 104 (94.0) 37 (96.7) 44 (100.0) 4 16
PT-NS (≥32 mg/liter; n = 1,449) 2 (0.1) 15 (1.2) 113 (9.0) 326 (31.5) 442 (62.0) 340 (85.4)a 125 (94.1) 42 (97.0) 44 (100.0) 4 16
NS to CAZ, MEM, and PT (n = 607) 1 (0.2) 15 (2.6) 88 (17.1) 154 (42.5) 174 (71.2)a 98 (87.3) 36 (93.2) 41 (100.0) 8 32
Levofloxacin-NS (≥4 mg/liter; n = 1,868) 19 (1.0) 84 (5.5) 332 (23.3) 459 (47.9) 508 (75.1) 286 (90.4)a 101 (95.8) 36 (97.7) 43 (100.0) 4 8
Gentamicin-NS (≥8 mg/liter; n = 873) 16 (1.8) 42 (6.6) 155 (24.4) 242 (52.1) 190 (73.9) 120 (87.6)a 46 (92.9) 25 (95.8) 37 (100.0) 2 16
Amikacin-NS (≥32 mg/liter; n = 224) 6 (2.7) 13 (8.5) 38 (25.4) 52 (48.7) 46 (69.2) 23 (79.5)a 17 (87.1) 10 (91.5) 19 (100.0) 4 32
Colistin-NS (≥4 mg/liter; n = 45) 1 (2.2) 1 (4.4) 17 (42.2) 15 (75.6) 5 (86.7) 1 (88.9)a 3 (95.6) 0 (95.6) 2 (100.0) 2 16
MDR (n = 1,151) 4 (0.3) 8 (1.0) 74 (7.5) 241 (28.4) 333 (57.3) 285 (82.1)a 118 (92.4) 42 (96.0) 46 (100.0) 4 16
XDR (n = 698) 1 (0.1) 4 (0.7) 28 (4.7) 109 (20.3) 179 (46.0) 208 (75.8)a 88 (88.4) 36 (93.6) 45 (100.0) 8 32
PDR (n = 2) 2 (100.0) >32
a

Values in bold indicate percent susceptible to ceftazidime-avibactam.

b

Abbreviations: CAZ, ceftazidime; NS, nonsusceptible; MEM, meropenem; PT, piperacillin-tazobactam; MDR, multidrug resistant; XDR, extensively drug resistant; PDR, pan-drug resistant.